Stockreport

FDA Grants Priority Review of ImmunoGen’s Supplemental Biologics License Application for ELAHERE® (mirvetuximab soravtansine-gynx) in Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc.  (IMGN) 
Last immunogen, inc. earnings: 5/1 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.immunogen.com/investor-relations
PDF Priority Review Granted with PDUFA Date of April 5, 2024 WALTHAM, Mass.--(BUSINESS WIRE)--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody- [Read more]